Skip to content

US · RARE · BIOTECHNOLOGY

Ultragenyx Pharmaceutical Inc. (RARE) intrinsic value and stock valuation

$16.48as of 2026-11-21 · Mkt cap 2.55B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Ultragenyx Pharmaceutical Inc. DCF and intrinsic value

InvestorsCraft values RARE with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from RARE’s statements →

Ultragenyx Pharmaceutical Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Novato, CA 94949 ultragenyx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$673M+19.9% 5y CAGRd
20112025
Net income
-$-575M
20112025
Free cash flow
-$-472M
20112025
Total equity
-$-73M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$673M$560.2M$434.3M$363.3M$351.4M
Operating income-$-535M-$-535.97M-$-569.21M-$-648.92M-$-381.74M
Net income-$-575M-$-569.18M-$-606.64M-$-707.42M-$-454.02M
EPSd-$-5.83M-$-6.29M-$-8.25M-$-10.12M-$-6.7M
Operating cash flow-$-466M-$-414.19M-$-474.81M-$-380.46M-$-338.69M
Capital expenditure-$-6M-$-7.49M-$-46.77M-$-146.12M-$-73.09M
Free cash flow-$-472M-$-421.68M-$-521.57M-$-526.59M-$-411.79M
Total assets$1.53B$1.5B$1.49B$1.55B$1.52B
Total debt$1.28B$40.3M$43.2M$31.6M$42M
Net debt$842M-$-133.39M-$-170.41M-$-101.35M-$-265.61M
Total equity-$-73M$262.3M$275.4M$352.5M$922.6M
Cash and short-term investments$693M$610M$577.2M$747.8M$740.2M
Income statement
20252024202320222021
Revenue$673M$560.2M$434.3M$363.3M$351.4M
Cost of revenue$109M$76.7M$45.2M$28.3M$16M
Gross profit$564M$483.5M$389M$335M$335.4M
Research and development expenses$750M$697.9M$648.5M$705.8M$497.2M
Selling, general and administrative expenses$349M$321.6M$309.8M$278.1M$220M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$1.1B$1.02B$958.3M$983.9M$717.1M
Cost and expenses$1.21B$1.1B$1B$1.01B$733.1M
Interest income$25M$36.5M$26.7M$11.1M$1.93M
Interest expense$62M$63M$66M$43M$29.4M
Depreciation and amortization$35M$35.5M$26M$18.2M$13.2M
Ebitda-$-474M-$-469M-$-516.45M-$-640.49M-$-410.32M
Operating income-$-535M-$-535.97M-$-569.21M-$-648.92M-$-381.74M
Total other income/expenses, net-$-36M-$-31.61M-$-39.26M-$-52.81M-$-71.24M
Income before tax-$-571M-$-567.59M-$-608.46M-$-701.73M-$-452.98M
Income tax expense$4M$1.6M-$-1.82M$5.7M$1.04M
Net income-$-575M-$-569.18M-$-606.64M-$-707.42M-$-454.02M
Weighted average shares outstanding$98.6M$90.5M$73.5M$69.9M$67.8M
Weighted average diluted shares outstanding$98.6M$90.5M$73.5M$69.9M$67.8M
Balance sheet
20252024202320222021
Cash and short-term investments$693M$610M$577.2M$747.8M$740.2M
Net receivables$159M$121.8M$73.4M$40.5M$44.4M
Inventory$52M$45M$34M$26.8M$16.2M
Total current assets$951M$817.1M$732.2M$883.9M$856.6M
Property, plant and equipment, net$267M$265.9M$290.6M$259.7M$176.2M
Goodwill and intangible assets$220M$222.7M$210.7M$204.5M$175.2M
Long-term investments$59M$135M$199.9M$149M$293.9M
Total non-current assets$581M$686.3M$758.8M$661.5M$665.8M
Total assets$1.53B$1.5B$1.49B$1.55B$1.52B
Accounts payable$31M$38.8M$42.1M$43.3M$17.1M
Short-term debt$81M$10.3M$12.6M$11.8M$11.1M
Deferred revenue$0.00$0.00$0.00$1.48M$7.61M
Total current liabilities$384M$344.2M$280.4M$261.2M$181.4M
Long-term debt$1.2B$30M$30.6M$19.8M$30.9M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$1.47M
Total non-current liabilities$1.22B$897M$935.2M$931.7M$418.5M
Capital lease obligations$24M$40.3M$43.2M$31.6M$42M
Total liabilities$1.61B$1.24B$1.22B$1.19B$599.8M
Common stock$0.00$90K$80K$70K$70K
Retained earnings-$-4.53B-$-3.96B-$-3.39B-$-2.78B-$-2.07B
Accumulated other comprehensive income (loss)$1M-$-640K$650K-$-6.57M-$-1.4M
Total equity-$-73M$262.3M$275.4M$352.5M$922.6M
Total investments$318M$571.3M$563.5M$763.8M$726.5M
Total debt$1.28B$40.3M$43.2M$31.6M$42M
Net debt$842M-$-133.39M-$-170.41M-$-101.35M-$-265.61M
Cash flow statement
20252024202320222021
Net income-$-575M-$-569.18M-$-606.64M-$-707.42M-$-454.02M
Depreciation and amortization$35M$35.5M$26M$18.2M$13.2M
Stock-based compensation$153M$158M$135.2M$130.4M$105M
Change in working capital-$-23M$13.9M-$-15.1M$60.2M-$-63.24M
Accounts receivable-$-31M-$-33.6M-$-22.78M-$-12.07M-$-5.43M
Inventory-$-6M-$-11.21M-$-6.93M-$-9.7M-$-3.12M
Accounts payable$24M$47M$2.38M$79.8M$2.81M
Net cash provided by operating activities-$-466M-$-414.19M-$-474.81M-$-380.46M-$-338.69M
Investments in property, plant and equipment-$-6M-$-7.49M-$-44.27M-$-116.12M-$-73.09M
Acquisitions, net$0.00$0.00$0.00-$-75.03M$0.00
Net cash used for investing activities$236M-$-17.77M$168M-$-291.65M-$-195.37M
Common stock issued$86M$381M$379.8M$0.00$78.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$478M$399.2M$388.1M$501.2M$118.6M
Net change in cash$253.5M-$-35.24M$81.8M-$-171.98M-$-416.71M
Cash at end of period$436M$184.2M$219.4M$137.6M$309.6M
Operating cash flow-$-466M-$-414.19M-$-474.81M-$-380.46M-$-338.69M
Capital expenditure-$-6M-$-7.49M-$-46.77M-$-146.12M-$-73.09M
Free cash flow-$-472M-$-421.68M-$-521.57M-$-526.59M-$-411.79M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Ultragenyx Pharmaceutical Inc.

        Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.

        CEO
        Emil D. Kakkis
        Employees
        1.37K
        Beta
        0.31

        Explore

        Frequently asked questions

        What is the intrinsic value of Ultragenyx Pharmaceutical Inc. (RARE)?

        Ultragenyx Pharmaceutical Inc. (RARE) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is RARE undervalued?

        RARE trades at a price of $16.48 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.